By in

Appointment of Cenkos Securities plc as Corporate Adviser and broker

Press Release                                                                                                                      2nd May 2019

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.  Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

Sativa Investments PLC 

 (“Sativa” or “the Company”)

Appointment of Cenkos Securities plc as Corporate Adviser and broker 

Sativa Group Plc (NEX: SATI), the UK’s leading quoted medicinal cannabis and wellness cannabidiol (CBD) group, has appointed Cenkos Securities plc (“Cenkos”) as its Corporate Adviser and broker with immediate effect.  

Geremy Thomas, founder and Chief Executive Officer of Sativa, said: “Cenkos is a top-ranking financial adviser and broker and has demonstrated its knowledge of the medicinal cannabis and CBD wellness industry by recently publishing a world-class and highly detailed industry note. 

“Cenkos’ appointment is in line with Sativa’s progression from, in only 15 months, being the UK’s first listed medicinal cannabis investment vehicle to its transition to a fully operational seed-to-consumer trading business.

“The UK medicinal cannabis industry has significant growth opportunities and we look forward to working with Cenkos on the Company’s next phase of development, which will include engaging with major institutional investors who are now showing an interest for medicinal cannabis and CBD wellness equities.” 

The Board of Sativa wish to thank Peterhouse for its support at the Company’s listing on the NEX Exchange in March 2018 and through its first 15 months of trading. 

The Directors of the Company accept responsibility for the contents of this announcement.


–  Ends –

For further information please contact:

Geremy Thomas

Founder & Chief Executive Officer

Sativa Investments PLC

+44 (0) 20 7971 1255


NEX Exchange Corporate Adviser

Corporate Finance 

Stephen Keys / Max Gould 

Cenkos Securities plc 

+44 (0) 20 7397 8900


Equity Sales 

 Julian Morse

Cenkos Securities

+44 (0) 20 7397 8900


Financial PR and IR

Abchurch Communications

Julian Bosdet / Dylan Mark /

Alejandra Campuzano

Abchurch Switchboard

Joseph Colliver

Chief Financial Officer

Sativa Investments PLC

+44 (0) 20 7971 1255

Notes to Editors

Sativa is a seed to Consumer medicinal cannabis and cannabidiol (CBD) wellness business, focused on the smart-sourcing of the raw material, advanced extraction, manufacture, testing, distribution, and research & development of medicinal cannabis and CBD products.  The Company has a Home Office licence application in process which, when granted as the Directors believe it will be as the application is in its final stages, will enable the Company to engage in the highly regulated process of growing, strictly for medicinal research & development purposes only, Tetrahydrocannabinol (THC) rich cannabis flowers at its high-security Somerset headquarters.   

The Company joined the UK’s NEX market in March 2018 as the UK’s first medicinal cannabis investment vehicle and since then has capitalised on its first-mover advantage, developing a substantial UK bridgehead into what the Company believes will be a significant market in the future.  Two UK operating subsidiaries, PhytoVista Laboratories and George Botanicals, are already well established and fully trading with healthy gross margins in independent CBD testing and CBD wholesale & retail respectively.   

Phytovista has conducted over 1000 independent tests and George Botanicals develops, manufactures and distributes low-THC CBD wellness products.  Other important future revenue streams are at various stages of development from concept to actual launch, with the first Goodbody CBD wellness centre opening in Bath on 28th June.   

Prior to the Listing, Sativa’s founder and CEO, Geremy Thomas, spent 12 months researching the global medical cannabis and CBD industries at his own personal expense.  He based himself in Canada, the most advanced country in terms of medicinal cannabis acceptance and regulation, travelling to America, Australia, the Far East, and Europe to connect with industry leaders and participants.  The Company on Listing was therefore already internationally connected, and this has given it a head start within the UK industry for smart-sourcing and the adoption of advanced value-add techniques and models.   

In May 2019 the Company obtained permission from NEX Exchange to reclassify itself as a trading company, having delivered on its original investment strategy.  Benefits of this include widening the appeal of the equity opportunity to additional types of investors including institutions and family offices, many of which are precluded from investing in fund-type vehicles.